84 related articles for article (PubMed ID: 16885384)
1. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Lin K; Glenn MA; Harris RJ; Duckworth AD; Dennett S; Cawley JC; Zuzel M; Slupsky JR
Cancer Res; 2006 Aug; 66(15):7801-9. PubMed ID: 16885384
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
[TBL] [Abstract][Full Text] [Related]
3. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
6. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
Chen YH; Peterson LC; Dittmann D; Evens A; Rosen S; Khoong A; Shankey TV; Forman M; Gupta R; Goolsby CL
Am J Clin Pathol; 2007 Feb; 127(2):182-91. PubMed ID: 17210531
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
11. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
12. Imatinib sensitizes CLL lymphocytes to chlorambucil.
Aloyz R; Grzywacz K; Xu ZY; Loignon M; Alaoui-Jamali MA; Panasci L
Leukemia; 2004 Mar; 18(3):409-14. PubMed ID: 14712290
[TBL] [Abstract][Full Text] [Related]
13. Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-κB signalling.
Pede V; Rombout A; Vermeire J; Naessens E; Vanderstraeten H; Philippé J; Verhasselt B
Br J Haematol; 2013 Dec; 163(5):621-30. PubMed ID: 24219331
[TBL] [Abstract][Full Text] [Related]
14. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
Abousamra NK; El-Din MS; Azmy E
Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
[TBL] [Abstract][Full Text] [Related]
15. c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis.
Vázquez MC; Vargas LM; Inestrosa NC; Alvarez AR
J Cell Physiol; 2009 Jul; 220(1):136-43. PubMed ID: 19306298
[TBL] [Abstract][Full Text] [Related]
16. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
17. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
Hewamana S; Lin TT; Rowntree C; Karunanithi K; Pratt G; Hills R; Fegan C; Brennan P; Pepper C
J Clin Oncol; 2009 Feb; 27(5):763-9. PubMed ID: 19124804
[TBL] [Abstract][Full Text] [Related]
18. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
19. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]